Marinus Pharmaceuticals Inc. | Mutual Funds
Mutual Funds that own Marinus Pharmaceuticals Inc.
FTIF SICAV - Franklin Biotechnology Discovery Fund
1,193,665
2.95%
140,600
0.37%
06/30/2018
Vanguard Total Stock Market Index Fund
974,897
2.41%
59,600
0%
07/31/2018
Prudential Jennison Health Sciences Fund
846,082
2.09%
0
0.24%
07/31/2018
iShares Russell 2000 ETF
761,852
1.88%
-408
0.01%
09/06/2018
Franklin Biotechnology Discovery Fund
614,520
1.52%
-182,500
0.3%
03/31/2018
iShares Nasdaq Biotechnology ETF
467,220
1.14%
-6,111
0.03%
09/06/2018
iShares Russell 2000 Growth ETF
357,463
0.88%
0
0.02%
09/06/2018
Vanguard Extended Market Index Fund
347,250
0.86%
0
0%
07/31/2018
Fidelity Spartan Extended Market Index Fund
116,446
0.28%
0
0%
07/31/2018
Highland Long/Short Healthcare Fund
105,605
0.26%
105,605
0.57%
12/31/2017
| Address |
170 North Radnor Chester Road
Radnor Pennsylvania 19087
United States
|
|
Employees
|
- |
| Website |
http://www.marinuspharma.com |
| Updated |
07/08/2019 |
| Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded by Geoffrey E. |
